NEW YORK (GenomeWeb News) – BioView and Kindstar Global this week announced an agreement granting Kindstar an exclusive license to validate and implement BioView's test for the early detection of lung cancer.

BioView's test is based on fluorescent in situ hybridization technology. Under the deal, Kindstar will purchase equipment and kits from BioView and will exclusively perform the test in China, Macau, Hong Kong, and Taiwan.

Beijing-based Kindstar has already successfully carried out a pilot study using BioView's assay, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.